122 related articles for article (PubMed ID: 15860690)
1. Ziprasidone pretreatment attenuates the lethal effects of cocaine in a mouse model.
Cleveland NJ; Dewitt CD; Heard K
Acad Emerg Med; 2005 May; 12(5):385-8. PubMed ID: 15860690
[TBL] [Abstract][Full Text] [Related]
2. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service.
Kohen I; Preval H; Southard R; Francis A
Am J Geriatr Pharmacother; 2005 Dec; 3(4):240-5. PubMed ID: 16503319
[TBL] [Abstract][Full Text] [Related]
3. Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam.
Martel M; Sterzinger A; Miner J; Clinton J; Biros M
Acad Emerg Med; 2005 Dec; 12(12):1167-72. PubMed ID: 16282517
[TBL] [Abstract][Full Text] [Related]
4. Assessment of propofol, midazolam and ziprasidone, or the combinations for the prevention of acute cocaine toxicity in a mouse model.
Yuksel A; Erdur B; Kortunay S; Ergin A
Environ Toxicol Pharmacol; 2013 Jan; 35(1):61-6. PubMed ID: 23257283
[TBL] [Abstract][Full Text] [Related]
5. Ziprasidone, diazepam, or the combination for prevention of cocaine toxicity in a mouse model.
Cleveland NR; Krier S; Heard K
Acad Emerg Med; 2007 Aug; 14(8):691-4. PubMed ID: 17576772
[TBL] [Abstract][Full Text] [Related]
6. Haloperidol (but not ziprasidone) withdrawal potentiates sensitization to the hyperlocomotor effect of cocaine in mice.
Fukushiro DF; Carvalho Rde C; Ricardo VP; Alvarez Jdo N; Ribeiro LT; Frussa-Filho R
Brain Res Bull; 2008 Sep; 77(2-3):124-8. PubMed ID: 18721669
[TBL] [Abstract][Full Text] [Related]
7. Use of antipsychotics to treat cocaine toxicity?
Wu S; Pearl-Davis MS; Manini AF; Hoffman RS
Acad Emerg Med; 2008 Jan; 15(1):105; author reply 106. PubMed ID: 18211326
[No Abstract] [Full Text] [Related]
8. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
[TBL] [Abstract][Full Text] [Related]
9. Effect of anxiolytic, antidepressant, and antipsychotic drugs on cocaine-induced seizures and mortality.
Macêdo DS; Santos RS; Belchior LD; Neto MA; Vasconcelos SM; Lima VT; Fonteles MM; Viana GS; de Sousa FC
Epilepsy Behav; 2004 Dec; 5(6):852-6. PubMed ID: 15582832
[TBL] [Abstract][Full Text] [Related]
10. Administration of ziprasidone for 10 days increases cocaine toxicity in mice.
Heard K; Krier S; Zahniser NR
Hum Exp Toxicol; 2008 Jun; 27(6):499-503. PubMed ID: 18784203
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of the prevention of relapse of schizophrenia in the longitudinal study Ziprasidone Extended Use in Schizophrenia (ZEUS).
Bernardo M; Azanza JR; Rubio-Terrés C; Rejas J
Actas Esp Psiquiatr; 2007; 35(4):259-62. PubMed ID: 17592789
[TBL] [Abstract][Full Text] [Related]
12. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Gibel A; Ritsner MS
Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
[TBL] [Abstract][Full Text] [Related]
13. Single-dose ziprasidone associated with QT interval prolongation.
Witsil JC; Zell-Kanter M; Mycyk MB
Am J Emerg Med; 2012 Jun; 30(5):837.e1-2. PubMed ID: 21641143
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Ratner Y; Gibel A; Yorkov V; Ritsner MS
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
[TBL] [Abstract][Full Text] [Related]
15. Agitation and/or aggression after traumatic brain injury in the pediatric population treated with ziprasidone. Clinical article.
Scott LK; Green R; McCarthy PJ; Conrad SA
J Neurosurg Pediatr; 2009 Jun; 3(6):484-7. PubMed ID: 19485732
[TBL] [Abstract][Full Text] [Related]
16. Pediatric ziprasidone overdose.
Fasano CJ; O'Malley GF; Lares C; Rowden AK
Pediatr Emerg Care; 2009 Apr; 25(4):258-9. PubMed ID: 19369840
[TBL] [Abstract][Full Text] [Related]
17. Ziprasidone monotherapy in bipolar II depression: an open trial.
Liebowitz MR; Salmán E; Mech A; Dunner D; Johnson AE; Akhtar J; Pratap R
J Affect Disord; 2009 Nov; 118(1-3):205-8. PubMed ID: 19264363
[TBL] [Abstract][Full Text] [Related]
18. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
Olié JP; Spina E; Murray S; Yang R
Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
[TBL] [Abstract][Full Text] [Related]
19. Physostigmine does not effect arousal but produces toxicity in an animal model of severe gamma-hydroxybutyrate intoxication.
Bania TC; Chu J
Acad Emerg Med; 2005 Mar; 12(3):185-9. PubMed ID: 15741579
[TBL] [Abstract][Full Text] [Related]
20. Ziprasidone in the treatment of delayed carbon monoxide encephalopathy.
Hu MC; Shiah IS; Yeh CB; Chen HK; Chen CK
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):755-7. PubMed ID: 16581170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
